Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008
Open Access
- 14 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e55486
Abstract
We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007–February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5–19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac™ introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.Keywords
This publication has 37 references indexed in Scilit:
- Seroprevalence of Serum Bactericidal Antibodies against Group W135 and Y Meningococci in England in 2009Clinical and Vaccine Immunology, 2012
- Study of a Localized Meningococcal Meningitis Epidemic in Burkina Faso: Incidence, Carriage, and ImmunityThe Journal of Infectious Diseases, 2011
- Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansNew England Journal of Medicine, 2011
- Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina FasoPLOS ONE, 2011
- Measurement of Functional Anti-Meningococcal Serogroup A Activity Using Strain 3125 as the Target Strain for Serum Bactericidal AssayClinical and Vaccine Immunology, 2011
- Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate VaccineClinical and Vaccine Immunology, 2011
- Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination EraClinical and Vaccine Immunology, 2008
- Seroprevalence of Bactericidal and Anti-Outer Membrane Vesicle Antibodies to Neisseria meningitidis Group B in EnglandClinical and Vaccine Immunology, 2007
- Molecular Characteristics and Epidemiology of Meningococcal Carriage, Burkina Faso, 2003Emerging Infectious Diseases, 2007
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977